Greg Troiano, MSE, Vice President of Technology and Chief Engineer, Seer, Inc.

Title TBA

Samir Mitragotri, PhD, Professor of Bioengineering at Harvard University, Core Faculty at Wyss Institute

Nanotechnology Quest to Overcome Biological Barriers of Drug Delivery (tentative)

Vladimir P. Torchilin, PhD, DSc, University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, School of Pharmacy, Bouve College of Health Sciences, Northeastern University

Next Generation of Drug Delivery Systems: Stimuli-Sensitive Combination Nanopreparations for Cancer

Marina A.Dobrovolskaia, Ph.D., MBA, PMP, Senior Principal Scientist, Head, Immunology Section, Nanotechnology Characterization Lab, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research

Achievements, Disappointments, and Lessons Learned from Immunotoxicity Studies of Nanotechnology-Formulated Complex Drugs

Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals

Clinical Translation of Non-targeted and Antibody-targeted Nanotherapeutics into the Clinic: Opportunities and Challenges

Konstantin Konstantinov, PhD, Senior Vice President Manufacturing and Process Sciences, Codiak BioSciences

Exosomes:  A New Therapeutic Modality and the Technology for Their Large Scale Manufacturing

Staci Sabnis, MS, Senior Scientist, Moderna Therapeutics

Messenger RNA as a Novel Therapeutic Approach

Johan Skog, PhD, Chief Scientific Officer, Exosome Diagnostics

Exosome Enrichment Enables Tissue Specific Liquid Biopsy Analysis

Kristy Wood, PhD, Senior Director, Intellia Therapeutics

Curative Therapeutics using Gene Editing CRISPR/Cas9 Technology (tentative)

Ken Bernstein, Senior Scientist, Nanomedicine Development and Manufacturing, Pfizer

ACCURINS Polymeric Nanoparticles: Considerations for Scale-up and Tech Transfer